Treats erectile dysfunction. ANDA 208960, held by Zydus Pharms. Vardenafil Hydrochloride.
As of Nov 16, 2026, ANDA 208960 (Vardenafil Hydrochloride), held by Zydus Pharms, was first approved by FDA on Oct 31, 2018, with 0 approved supplements and 0 published complete response letters.
Vardenafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2018 | Original application | Approved | None posted |
| Vardenafil HydrochlorideEQ 2.5MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 5MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 10MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 20MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters